Literature DB >> 33365025

Tumor-Associated Macrophages in Tumor Immunity.

Yueyun Pan1,2, Yinda Yu2, Xiaojian Wang2, Ting Zhang1,2.   

Abstract

Tumor-associated macrophages (TAMs) represent one of the main tumor-infiltrating immune cell types and are generally categorized into either of two functionally contrasting subtypes, namely classical activated M1 macrophages and alternatively activated M2 macrophages. The former typically exerts anti-tumor functions, including directly mediate cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC) to kill tumor cells; the latter can promote the occurrence and metastasis of tumor cells, inhibit T cell-mediated anti-tumor immune response, promote tumor angiogenesis, and lead to tumor progression. Both M1 and M2 macrophages have high degree of plasticity and thus can be converted into each other upon tumor microenvironment changes or therapeutic interventions. As the relationship between TAMs and malignant tumors becoming clearer, TAMs have become a promising target for developing new cancer treatment. In this review, we summarize the origin and types of TAMs, TAMs interaction with tumors and tumor microenvironment, and up-to-date treatment strategies targeting TAMs.
Copyright © 2020 Pan, Yu, Wang and Zhang.

Entities:  

Keywords:  immunosuppression; regulation; tumor microenvironment; tumor therapy; tumor-associated macrophages

Mesh:

Year:  2020        PMID: 33365025      PMCID: PMC7751482          DOI: 10.3389/fimmu.2020.583084

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  74 in total

1.  Macrophage phenotypic mechanomodulation of enhancing bone regeneration by superparamagnetic scaffold upon magnetization.

Authors:  Suisui Hao; Jie Meng; Yu Zhang; Jian Liu; Xin Nie; Fengxin Wu; Yanlian Yang; Chen Wang; Ning Gu; Haiyan Xu
Journal:  Biomaterials       Date:  2017-06-09       Impact factor: 12.479

2.  Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.

Authors:  Heiko Bruns; Maike Büttner; Mario Fabri; Dimitrios Mougiakakos; Jörg T Bittenbring; Markus H Hoffmann; Fabian Beier; Shirin Pasemann; Regina Jitschin; Andreas D Hofmann; Frank Neumann; Christoph Daniel; Anna Maurberger; Bettina Kempkes; Kerstin Amann; Andreas Mackensen; Armin Gerbitz
Journal:  Sci Transl Med       Date:  2015-04-08       Impact factor: 17.956

3.  Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor.

Authors:  Jing-Yiing Wu; Tsai-Wang Huang; Yi-Ting Hsieh; Yi-Fu Wang; Chia-Chien Yen; Guan-Lin Lee; Chang-Ching Yeh; Yi-Jen Peng; Ya-Yi Kuo; Hsiu-Ting Wen; Hui-Chen Lin; Cheng-Wen Hsiao; Kenneth K Wu; Hsing-Jien Kung; Yu-Juei Hsu; Cheng-Chin Kuo
Journal:  Mol Cell       Date:  2019-11-14       Impact factor: 17.970

4.  Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.

Authors:  Mingzhu Yin; Xia Li; Shu Tan; Huanjiao Jenny Zhou; Weidong Ji; Stefania Bellone; Xiaocao Xu; Haifeng Zhang; Alessandro D Santin; Ge Lou; Wang Min
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

5.  Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.

Authors:  Changbin Zhu; Dana Mustafa; Ping-Pin Zheng; Marcel van der Weiden; Andrea Sacchetti; Maarten Brandt; Ihsan Chrifi; Dennie Tempel; Pieter J M Leenen; Dirk Jan Duncker; Caroline Cheng; Johan M Kros
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

6.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

Review 7.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 8.  Tumor-associated macrophages as major players in the tumor microenvironment.

Authors:  Theerawut Chanmee; Pawared Ontong; Kenjiro Konno; Naoki Itano
Journal:  Cancers (Basel)       Date:  2014-08-13       Impact factor: 6.639

9.  Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages.

Authors:  Hao Wu; Yijie Han; Yasmina Rodriguez Sillke; Hongzhang Deng; Sophiya Siddiqui; Christoph Treese; Franziska Schmidt; Marie Friedrich; Jacqueline Keye; Jiajia Wan; Yue Qin; Anja A Kühl; Zhihai Qin; Britta Siegmund; Rainer Glauben
Journal:  EMBO Mol Med       Date:  2019-10-10       Impact factor: 12.137

10.  Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.

Authors:  Cristovão M Sousa; Douglas E Biancur; Xiaoxu Wang; Christopher J Halbrook; Mara H Sherman; Li Zhang; Daniel Kremer; Rosa F Hwang; Agnes K Witkiewicz; Haoqiang Ying; John M Asara; Ronald M Evans; Lewis C Cantley; Costas A Lyssiotis; Alec C Kimmelman
Journal:  Nature       Date:  2016-08-10       Impact factor: 49.962

View more
  157 in total

1.  Tumor-associated macrophages of the M1/M2 phenotype are involved in the regulation of malignant biological behavior of breast cancer cells through the EMT pathway.

Authors:  Zhuo Chen; Jing Wu; Liang Wang; Hua Zhao; Jie He
Journal:  Med Oncol       Date:  2022-05-16       Impact factor: 3.064

Review 2.  Nanozyme-Based Enhanced Cancer Immunotherapy.

Authors:  Ngoc Man Phan; Thanh Loc Nguyen; Jaeyun Kim
Journal:  Tissue Eng Regen Med       Date:  2022-01-31       Impact factor: 4.169

3.  Impact of the tumor immune microenvironment on the outcome of pancreatic cancer: a retrospective study based on clinical pathological analysis.

Authors:  Hui Huang; Jichun Sun; Zhiqiang Li; Xianlin Zhang; Zheng Li; Hongwei Zhu; Xiao Yu
Journal:  Gland Surg       Date:  2022-02

4.  Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.

Authors:  Kehui Liu; Yezhou Ding; Yun Wang; Qingqing Zhao; Lei Yan; Jingdong Xie; Yunye Liu; Qing Xie; Wei Cai; Shisan Bao; Hui Wang
Journal:  Clin Exp Med       Date:  2022-03-28       Impact factor: 3.984

Review 5.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  The clinical relevance of unfolded protein response signaling in breast cancer.

Authors:  Masanori Oshi; Arya Mariam Roy; Shipra Gandhi; Yoshihisa Tokumaru; Li Yan; Akimitsu Yamada; Itaru Endo; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

7.  IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma.

Authors:  Ann-Kristin Struckmeier; Anne Radermacher; Michael Fehrenz; Tamara Bellin; Dalia Alansary; Philipp Wartenberg; Ulrich Boehm; Mathias Wagner; Anja Scheller; Jochen Hess; Julius Moratin; Christian Freudlsperger; Jürgen Hoffmann; Lorenz Thurner; Klaus Roemer; Kolja Freier; Dominik Horn
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-13       Impact factor: 4.322

Review 8.  The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer.

Authors:  Bruce A Bunnell; Elizabeth C Martin; Margarite D Matossian; Courtney K Brock; Khoa Nguyen; Bridgette Collins-Burow; Matthew E Burow
Journal:  Cancer Metastasis Rev       Date:  2022-08-24       Impact factor: 9.237

9.  Mapping trends and hotspots regarding oral carcinoma and macrophages: a bibliometric analysis of global research.

Authors:  Tuan Zhao; Hao Hu; Xuan Chen; Ye Liu; Heng Wang; Xiaomei Li
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

10.  Comparative Proteomic Analysis of Polarized Human THP-1 and Mouse RAW264.7 Macrophages.

Authors:  Pengfei Li; Zhifang Hao; Jingyu Wu; Chen Ma; Yintai Xu; Jun Li; Rongxia Lan; Bojing Zhu; Pengyu Ren; Daidi Fan; Shisheng Sun
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.